key: cord-0741387-priauadk
authors: Van der Ent, Martijn A.; Svilar, David; Cleuren, Audrey C.A.
title: Molecular analysis of vascular gene expression
date: 2022-05-19
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12718
sha: 1668c0fbd6bea66474844bdb291da3f278484a5d
doc_id: 741387
cord_uid: priauadk

A State of the Art lecture entitled “Molecular Analysis of Vascular Gene Expression” was presented at the ISTH Congress in 2021. Endothelial cells (ECs) form a critical interface between the blood and underlying tissue environment, serving as a reactive barrier to maintain tissue homeostasis. ECs play an important role in not only coagulation, but also in the response to inflammation by connecting these two processes in the host defense against pathogens. Furthermore, ECs tailor their behavior to the needs of the microenvironment in which they reside, resulting in a broad display of EC phenotypes. While this heterogeneity has been acknowledged for decades, the contributing molecular mechanisms have only recently started to emerge due to technological advances. These include high‐throughput sequencing combined with methods to isolate ECs directly from their native tissue environment, as well as sequencing samples at a high cellular resolution. In addition, the newest technologies simultaneously quantitate and visualize a multitude of RNA transcripts directly in tissue sections, thus providing spatial information. Understanding how ECs function in (patho)physiological conditions is crucial to develop new therapeutics as many diseases can directly affect the endothelium. Of particular relevance for thrombotic disorders, EC dysfunction can lead to a procoagulant, proinflammatory phenotype with increased vascular permeability that can result in coagulopathy and tissue damage, as seen in a number of infectious diseases, including sepsis and coronavirus disease 2019. In light of the current pandemic, we will summarize relevant new data on the latter topic presented during the 2021 ISTH Congress.

The vascular system extends to almost all tissues in the body, thereby providing oxygen and nutrients while removing waste products, via an intricate network of arteries and veins that are connected by capillaries. [1] [2] [3] Endothelial cells (ECs) form the inner lining of these vessels, where they not only provide a physical barrier between the blood and underlying cells but also act as a reactive interface to maintain tissue homeostasis. In addition to controlling vascular permeability and the extravasation of fluids and solutes, ECs regulate hemostasis and inflammation, as well as vasomotor tone, cell adhesion, and angiogenesis, and have been shown to participate in both innate and adaptive immune responses. 4, 5 They also fulfill unique roles depending on their anatomic location along the vascular tree and the specific needs of the underlying tissue. To achieve all these functions, ECs display a remarkable heterogeneity. [1] [2] [3] While long recognized, the molecular mechanisms underlying this heterogeneity have only started to emerge in recent years, 2,3,6,7 as the EC's microenvironmental interdependence, and interspersed and sparse distribution initially precluded direct in vivo analysis. As the integrity of the endothelium is essential to maintain tissue homeostasis, understanding how ECs function under physiological and pathological conditions is crucial in developing new therapeutics for many diseases, including thrombotic disorders.

In this review, we will first discuss ECs as an integral part of the blood coagulation system, and as an important mediator of the intricate connections between coagulation and inflammation, a topic that has received considerable attention due to the ongoing coronavirus disease 2019 (COVID- 19) pandemic. Next, we will provide an overview of methods to perform (endothelial) cell type-specific molecular analyses. Here, we will not only highlight current approaches focused on transcriptomics, such as single-cell RNA sequencing, but also discuss emerging techniques providing spatial information and combining different -omics approaches to further understand the complexity of biological systems such as the vasculature. Finally, we will present an update from the XXIX Congress of the ISTH, with a specific emphasis on the role of endothelial dysfunction in COVID-19.

The endothelium plays a key role in hemostasis by maintaining blood in a fluid state under normal conditions, while facilitating rapid and localized thrombus formation at the site of vessel injury. 8, 9 ECs achieve this by tightly regulating platelet adhesion and activation and controlling procoagulant, anticoagulant, and fibrinolytic processes ( Figure 1 ).

Healthy endothelium is covered by the glycocalyx, which contains glycosaminoglycans known for their anticoagulant properties. 10 Furthermore, ECs produce nitric oxide and prostacyclin, and express ecto-adenophosphatase on their cell surface that keep platelets in a resting state. 11 However, platelet recruitment and thrombus formation upon vessel injury is essential to limit blood loss and tissue damage. This process starts with perivascular tissue factor (TF) exposure that binds and activates factor VII (FVII) to initiate the coagulation cascade. In addition, ultra-large von Willebrand factor (VWF) is released from the endothelium and forms a bridge between platelets and extracellular matrix components. This latter interaction mediates shear stress-dependent platelet activation and aggregation, which further promotes coagulation and provides a surface for thrombus formation.

To prevent pathological thrombosis, coagulation is tightly regulated by 3 main anticoagulant systems aimed at limiting thrombin generation, which are driven by tissue factor pathway inhibitor (TFPI), antithrombin (AT), and the protein C pathway. 12 TFPI is a factor X-dependent inactivator of TF/activated FVII (FVIIa), and ECs express both the secreted TFPIα and the membrane-anchored TFPIβ isoform. 13 While AT is synthesized by hepatocytes and is present in plasma, its function is strongly enhanced upon interaction with heparan sulfates present in the glycocalyx covering the endothelium. 14 In addition to its main targets, thrombin (activated factor II

[FIIa]) and activated factor X, AT can also inactivate other serine proteases within the coagulation cascade. Activation of the protein C pathway is initiated by binding of thrombin to thrombomodulin (TM), which has several consequences: not only does this binding reduce the amount of FIIa in the circulation, thus limiting further fibrin formation, it also activates thrombin-activatable fibrinolysis inhibitor, which stabilizes fibrin clots. 15 Finally, by binding to TM, thrombin is converted into a protein with anticoagulant properties via protein C activation, a process augmented in the presence of the endothelial protein C receptor (EPCR). Activated protein C, together with ECderived protein S, can subsequently suppress coagulation via proteolysis of activated factor V and activated factor VIII.

As the vessel is repaired, clot resolution occurs through fibrinolysis via tissue-type plasminogen activator (t-PA) that is expressed by ECs and converts plasminogen into plasmin, leading to subsequent fibrin degradation. This process is inhibited by plasminogen activator inhibitor 1 (PAI-1), which is produced by several cell types, including ECs. 16 

Given its unique location between the blood and underlying parenchyma, ECs are often referred to as "gatekeepers" that maintain normal tissue homeostasis. 2, 3, 17 In addition to their role in coagulation, the endothelium has immunological functions, and both systems work together in host defense responses. 5, [18] [19] [20] This is particularly evident in immunothrombosis, where inflammation triggers coagulation as part of the host's reaction to pathogen invasion to contain and eliminate the threat, thereby preventing its dissemination throughout the vasculature and limiting tissue damage ( Figure 1 ). 18, 21 Recognition and binding of pathogens by traditional immune cells and endothelial cells triggers their activation and release of proinflammatory cytokines and chemokines. 4, 5 Well known for their roles in regulating the immune response and inflammation, these mediators can further affect ECs in several ways. 22, 23 First, they lead to upregulated expression of cell adhesion molecules necessary for leukocyte recruitment and extravasation into the underlying tissue. Cytokines also induce degradation of the glycocalyx, which not only affects its anticoagulant properties 10 but also contributes to increased vascular permeability, which is further enhanced by breakdown of junction proteins that interconnect the endothelium.

In addition, cytokines stimulate the release of microvesicles, trigger the formation of neutrophil extracellular traps and activate the complement system. 19, 21 All these components can directly influence both coagulation and inflammation, highlighting the extensive crosstalk between these two processes.

Cytokines can alter levels of coagulation and fibrinolytic factors, thereby shifting the endothelium from an anticoagulant to a procoagulant state. 18, 19, 21 Central in this process is the cytokine- Together, the interaction between inflammation and coagulation leads to robust thrombus formation to contain and remove the pathogen from the circulation. However, it is important to note that as with hemostasis, immunothrombosis requires careful regulation, as an exaggerated procoagulant response without sufficient suppression by natural inhibitors can lead to thromboinflammation. 18, 21 The latter can result in significant organ injury, potentially leading to organ failure and even death, as can be observed in severe sepsis and COVID-19. 22,23,27,28 F I G U R E 1 Endothelial contributions to hemostasis and immunothrombosis. ECs play a role in hemostasis via expression of (1) factors that prevent platelet aggregation, (2) procoagulant VWF, which recruits and activates platelets upon vessel injury, (3) several anticoagulant factors that limit thrombin formation and (4) pro-and antifibrinolytic factors that are important for thrombus resolution. (5) Pathogen exposure activates immune cells and ECs, which stimulates cytokine release that induce expression of adhesion molecules leading to leukocyte recruitment and extravasation, shedding of the glycocalyx, and vascular leakage. Cytokines also (6) upregulate tissue factor expression on immune cells and activation of ECs leading to thrombin generation, while at the same time causing (7) a decrease in production of anticoagulant factors and (8) a shift toward inhibition of fibrinolysis, thereby resulting in (9) thrombus formation containing the pathogen. ADPase, adenophosphatase; aPC, activated protein C; AT, antithrombin; ECs, endothelial cells; EPCR, endothelial protein C receptor; FIIa, activated factor II; FVa, activated factor V; FVIIa, activated factor VII; FVIIIa, activated factor VIII; FXa, activated factor X; NO, nitric oxide; PAI-1, plasminogen activator inhibitor 1; PGI 2 , prostacyclin; TF, tissue factor; TFPI, tissue factor pathway inhibitor; VWF, von Willebrand factor 4 | EC HE TEROG ENEIT Y ECs are highly heterogeneous across organs, but also along different segments of the vascular tree. 1-3 As a result, ECs have distinct responses to stimuli depending on the vascular bed in which they reside. With respect to thrombosis, alterations in circulating levels of pro-or anticoagulant factor may result in site-specific manifestations, for example, as observed in thrombotic microangiopathies such as thrombotic thrombocytopenic purpura (TTP). 29 However, while linked to abnormal VWF homeostasis, TTP does not lead to a general disseminated thrombotic phenotype, but instead predominantly affects the kidney and central nervous system. The idea of a tissue-specific response is further reinforced by observations in mice deficient in (anti)coagulant factors, as they also display lesions associated with distinct segments of the vascular tree. 30 It has long been speculated that vascular site-specific thrombosis phenotypes may be explained by unique expression patterns of ECderived coagulation factors. 31 However, demonstrating EC heterogeneity on a molecular level has been challenging since ECs not only form an integral part of a tissue, but they typically represent a small percentage of the total number of cells in an organ. 32 Therefore, early studies tried to assess gene expression by isolating ECs and evaluating them in vitro. While these studies have yielded important information, we and others have shown that extracting ECs from their native microenvironment and expanding them in culture induces phenotypic drift. [32] [33] [34] This drift leads to changes in expression profiles and the loss of tissue-specific traits, thus not forming a true representative for their in vivo counterparts. Recognizing the importance of the natural EC environment, past approaches used histology-based methods such as immunohistochemistry or in situ hybridization assays to determine expression patterns, showing distinct patterns for TFPI, EPCR, and t-PA expression, whereas TM is ubiquitously expressed. [35] [36] [37] [38] The distribution of VWF across the vascular tree has been the focus of several research groups, demonstrating by histology as well as the generation of transgenic mouse models, that VWF is more abundant in ECs of large vessels as compared to the microvasculature. [39] [40] [41] [42] Furthermore, VWF is predominantly expressed in the venous rather than the arterial system.

Although these latter methods provide information on the spatial distribution of proteins and RNA, they are limited by the ability to study only one or a few genes at the same time.

The introduction of high-throughput approaches, particularly transcriptomic analysis, has vastly improved our understanding of cellular and molecular biology over the past two decades. 43 However, microarray or bulk RNA sequencing (RNASeq) data from intact tissues provides an average representation of transcript levels originating from all cell types present, and does not permit deconvolution of cell-specific expression profiles. As ECs typically form only a minor fraction of the total cell content, variations in expression profiles are likely masked by differences in more abundant cell types.

To overcome these limitations, several methods can be used to enrich for ECs prior to high-throughput analyses, via either nongenetic or genetic methods requiring transgenic animals.

An important advantage of methods not relying on genetic manipulations to characterize cells is that they can also be used in nonmodel species (Table 1 ). An example of such a method is laser microdissection (LMD), where cells of interest are identified based on morphological features and isolated directly from tissue sections. 44 Cells can then be processed for further downstream applications, including high-throughput transcriptomic or proteomic analyses. 45 A limitation of this technique is that the identification of cells must be done manually to avoid contamination with neighboring cells. It is therefore very time consuming, and results are highly dependent on the expertise of the operator. Alternatively, immunostaining can be performed to help with this process, although these additional sample manipulations can affect RNA or protein integrity. 46 It is also important to note that even with these precautions, contamination can still occur, as cells below the dissection plane cannot be directly visualized. However, LMD allows for preservation of tissue architecture, which is highly valuable in evaluating spatial heterogeneity (Table 1) , and it is therefore not surprising that LMD has been previously used to unmask molecular profiles of specific (micro)vascular segments. 45 Another approach not relying on transgenic animals per se, is flow sorting by fluorescence-activated cell sorting (FACS). Here, tissues are enzymatically dissociated to obtain a single cell suspension, followed by incubation with a fluorescently labeled antibody against a cell surface marker specific for the cell type of interest.

While labeling of cells often occurs ex vivo, the unique position of the endothelium also allows for direct in vivo staining prior to tissue dissociation via intravital labeling, a method employed to show that tissue-specific ECs establish specialized vascular niches. 47 An important caveat for this approach is that flow sorting requires the preparation of single cell suspensions. The resulting disruption of cell-cell contacts, especially for ECs, may lead to stress-induced transcriptional changes. 32, 34 In addition, exposure to rapid flow may cause mechanical damage, further affecting gene expression or even result in cell death, thus introducing a potential selection bias. 43 Despite these limitations, FACS is widely used for selecting large numbers of cells for a specific population in an automated fashion, with minimal contamination (Table 1) .

Many studies have used RNASeq analyses to evaluate the isolated cell types at a molecular level, as these provide genome-wide coverage, great precision, and are accessible to many researchers.

However, there is not always a direct correlation between mRNA and actual protein levels. 48, 49 To directly assess protein levels in an unbiased manner, proteomic approaches can be applied. While these methods are often used to study intracellular protein levels, several groups have focused their attention on the luminal surface of the endothelium, which is in immediate contact with the blood. [50] [51] [52] Not surprisingly, these studies also identified (interactive regions of) proteins being present in organ-specific patterns, and this knowledge could potentially be used to develop methods and therapeutics that target specific vascular beds.

As noted above, FACS is widely used to identify and isolate cell types of interest. However, its success is dependent on the availability of reliable, validated antibodies, which are still often lacking for (tissue-specific) endothelial subsets. As an alternative, genetic means can be used to express fluorescent proteins on the surface of a specific cell type 53 (Figure 2 ). Although the in vivo labeling in these reporter animals has advantages, the downstream analyses are not free from the previously discussed limitations associated with FACS ( Table 1) .

To circumvent these problems, strategies have been developed to isolate cell-specific RNA directly from the in vivo environment.

One such approach is thiouracil (TU) tagging, which besides cell specificity also incorporates a temporal component, and has been used to identify intraorgan heterogeneity in nascent endothelial RNA levels ( Figure 2) . 54 An alternative approach to evaluate expression programs from distinct cell types is translating ribosome affinity purification (TRAP). Here, a ribosomal protein is labeled with either a fluorescent 55-57 or hemagglutinin epitope tag 32, 58, 59 in the cell population of interest ( Figure 2 ). Incorporation of these tagged proteins into ribosomal complexes allows for immunoprecipitation of polysomes with their associated actively translating mRNA, which can be further processed for high-throughput analyses. By combining in vivo perfusion using a translation inhibitor such as cycloheximide, with the mechanic disruption of frozen tissues, we have previously shown that TRAP provides an accurate snapshot of EC-specific expression profiles, and identified a high degree of EC heterogeneity across organs in naïve mice as well as organ-specific EC reactivity after lipopolysaccharide exposure. 32 The previously described genetic methods all focus on transcript levels, ranging from newly transcribed RNA (TU tagging) to actively translated RNA (TRAP models) ( Table 1 ). The latter, also known as the translatome, has been demonstrated to correlate better to actual protein levels (proteome) as compared to the transcriptome, and might therefore be a better predictor for protein abundance. 48, 49 However, it is also important to understand how regulatory programs control cellular and molecular heterogeneity, which can be This can be achieved via the use of an intermediate recombinase system such as Dre-rox, which has been previously used to specifically target brain and coronary ECs 68 or via the split-Cre system. 69

Although the above methods to study ECs have yielded valuable insights into organ specificity, they do not permit resolution at the (Table 1 ). In situ hybridization (ISH) assays do provide this information, particularly single-molecule fluorescence ISH (sm-FISH). The design of the gene-specific fluorescent probes makes it possible to visualize single RNA molecules while preserving tissue morphology, and therefore it has been widely used to validate sequencing data and further investigate cell-cell interactions. 43 However, smFISH has been limited by the ability to only evaluate a few transcripts at the same time due to the overlapping spectra of fluorescent probes.

Therefore, early studies combined scRNASeq with smFISH,

where transcripts unique to cellular subsets are identified by scRNASeq and validated by smFISH thereby providing information on the position of these cells within the tissue. 71 Conversely, differential expression of transcripts known to be spatially restricted, so-called zonated landmark genes, can be used to identify cell clusters in scRNASeq data. 86 An alternative method is spatial sorting,

where scRNASeq data are used to specifically identify surface markers that are unique to distinct cellular subsets. 87 This has the advantage that instead of single cells, single-cell (sub)populations can be isolated, allowing for high-resolution bulk multi-omics analyses, including high-sensitivity transcriptomics and proteomics analysis.

Additional methods to measure RNA levels directly in tissue sections have been developed. 6, 43, 88 These are based on a combination of quantitative gene expression data and visualization of transcripts or proteins, thereby providing spatial information (Table 1 ). In general, these can be divided into targeted and untargeted approaches, with the latter including methods such as fluorescence in situ hybridization sequencing 89 

ECs play a key role in the coagulation system by producing both pro-and anticoagulant factors to ensure local hemostasis. As an integral component of the immune system, ECs also form an important mediator in the host defense response by connecting coagulation and inflammatory processes to contain and eliminate pathogens. This is a very delicate balance that can be easily disturbed and lead to coagulopathy as seen in sepsis and COVID-19, a highly discussed topic at the ISTH 2021 Congress. Developing a better understanding of how ECs regulate these processes will not only provide insights into thrombosis and thromboinflammation, but could also help identify potential targets to prevent these pathological events.

Studying ECs is complicated by their extensive heterogeneity and high degree of dependence on the microenvironment in which they reside. Technological advances over the past decades have provided important information on the molecular mechanisms underlying this heterogeneity, both on an organ-wide level and more recently at single-cell resolution. The introduction of (commercially available) spatial transcriptomics platforms, as well as the growing possibilities to integrate multi -omics data sets will undoubtedly further contribute to this knowledge.

With ECs forming a large therapeutic target, capitalizing on established molecular differences in EC reactivity under (patho) physiologic conditions can pave the way for developing effective antithrombotic therapies without inducing adverse effects such as an increased bleeding risk, an important unmet clinical need.

The authors thank Dr David Ginsburg for careful reading of the manuscript. DS and AC are supported by grants from the National Institutes of Health (T32HL007622 and K12HD028820 to DS;

R03AG070541 to AC). Figures were created using BioRender.

The authors have no conflicts of interest to disclose.

ME, DS, and AC wrote, edited, and approved the final version of the manuscript.

Audrey C.A. Cleuren https://orcid.org/0000-0003-1384-4651

Phenotypic heterogeneity of the endothelium: I

Structure, function, and mechanisms

Organotypic vasculature: from descriptive heterogeneity to functional pathophysiology

Vascular heterogeneity and specialization in development and disease

An evolving new paradigm: endothelial cells-conditional innate immune cells

Vascular endothelial cells and innate immunity

Single cell analysis in vascular biology

Single-cell RNA sequencing in cardiovascular development, disease and medicine

Role of endothelial cells in acute and chronic thrombosis

Thrombotic regulation from the endothelial cell perspectives

Glycosaminoglycan neutralization in coagulation control

Circulating platelets as mediators of immunity, inflammation, and thrombosis

Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases

Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein

Antithrombin: a new look at the actions of a serine protease inhibitor

The anticoagulant protein C pathway

Recognition of plasminogen activator inhibitor type 1 as the primary regulator of fibrinolysis

Endothelial cell heterogeneity. Cold Spring Harb Perspect Med

Thrombosis as an intravascular effector of innate immunity

Cross talk pathways between coagulation and inflammation

Infections and endothelial cells

Interplay between inflammation and thrombosis in cardiovascular pathology

Endothelial responses in sepsis

The role of endothelial shear stress on haemodynamics, inflammation, coagulation and glycocalyx during sepsis

Molecular basis of protease-activated receptor 1 signaling diversity

Protein C anticoagulant system-anti-inflammatory effects

Antithrombin: antiinflammatory properties and clinical applications

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

The coagulopathy, endotheliopathy, and vasculitis of COVID-19

Endothelial cells and thrombotic microangiopathy

Transgenic mouse models of venous thrombosis: fulfilling the expectations?

Vascular-bed-specific hemostasis and hypercoagulable states

The in vivo endothelial cell translatome is highly heterogeneous across vascular beds

Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment

Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture

Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues

Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway

Localization of tissue plasminogen activator in the endothelium of a limited number of vessels

Targeting of transgene expression to the vascular endothelium of mice by homologous recombination at the thrombomodulin locus

Characterization of the mouse von Willebrand factor promoter

Heterogeneous distribution of thrombomodulin and von Willebrand factor in endothelial cells in the human pulmonary microvessels

Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues

Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo

RNA sequencing: the teenage years

Laser capture microdissection: methods and applications

Innovations in studying in vivo cell behavior and pharmacology in complex tissuesmicrovascular endothelial cells in the spotlight

Development of rapid staining protocols for laser-capture microdissection of brain vessels from human and rat coupled to gene expression analyses

Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration

On the dependency of cellular protein levels on mRNA abundance

Transcriptome and translatome co-evolution in mammals

Steps toward mapping the human vasculature by phage display

Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display

Proteomic atlas of organ vasculopathies triggered by Staphylococcus aureus sepsis

Fluorescent reporter transgenic mice for in vivo live imaging of angiogenesis and lymphangiogenesis

Mouse TU tagging: a chemical/ genetic intersectional method for purifying cell type-specific nascent RNA

A translational profiling approach for the molecular characterization of CNS cell types

Evaluation of TRAP-sequencing technology with a versatile conditional mouse model

Interrogating translational efficiency and lineage-specific transcriptomes using ribosome affinity purification

Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation

Celltype-specific isolation of ribosome-associated mRNA from complex tissues

Transcriptional and epigenomic landscapes of CNS and non-CNS vascular endothelial cells. eLife

The INTACT method for cell type-specific gene expression and chromatin profiling in Arabidopsis thaliana

Inducible cellspecific mouse models for paired epigenetic and transcriptomic studies of microglia and astroglia

Simultaneous transcriptional and epigenomic profiling from specific cell types within heterogeneous tissues in vivo

Endothelial-specific Cre mouse models

Specification and function of hemogenic endothelium during embryogenesis

Nonparallel recombination limits Cre-LoxP-based reporters as precise indicators of conditional genetic manipulation

Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo

Genetic targeting of organ-specific blood vessels

Split-Cre complementation indicates coincident activity of different genes in vivo

Biological and medical importance of cellular heterogeneity deciphered by single-cell RNA sequencing

A molecular atlas of cell types and zonation in the brain vasculature

Capillary cell-type specialization in the alveolus

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets

Molecular profiling of coronavirus disease 2019 (COVID-19) autopsies uncovers novel disease mechanisms

A single-cell transcriptomic landscape of the lungs of patients with COVID-19

Progress and applications of singlecell sequencing techniques

The human body at cellular resolution: the NIH human biomolecular atlas program

Mapping the mouse cell atlas by microwell-seq

The human cell atlas

Overall Coordination; Logistical Coordination, et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris

Single-cell transcriptome atlas of murine endothelial cells

Single-cell RNA sequencing unveils unique transcriptomic signatures of organ-specific endothelial cells

Single cell analysis of endothelial cells identified organ-specific molecular signatures and heart-specific cell populations and molecular features

PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data

EndoDB: a database of endothelial cell transcriptomics data

Single-cell spatial reconstruction reveals global division of labour in the mammalian liver

A spatial vascular transcriptomic, proteomic, and phosphoproteomic atlas unveils an angiocrine Tie-Wnt signaling axis in the liver

The Pandora's box of novel technologies that may revolutionize lung cancer

Highly multiplexed subcellular RNA sequencing in situ

Single-cell systems biology by super-resolution imaging and combinatorial labeling

Single-cell in situ RNA profiling by sequential hybridization

Multiplex digital spatial profiling of proteins and RNA in fixed tissue

High-Plex multiomic analysis in FFPE tissue at single-cellular and subcellular resolution by spatial molecular imaging

RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells

Single-cell proteomics: progress and prospects

Coagulopathy in COVID-19

COVID-19 coagulopathy: is it disseminated intravascular coagulation?

Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses

Endothelial cell dysfunction, coagulation

The link between inflammation, coagulation and endothelium damage in COVID-19: evidence from an exploratory cross-sectional study

Immunothrombosis biomarkers for distinguishing COVID-19 patients from non-COVID septic pneumonia patients and for predicting ICU mortality

Distinctive biomarker features in the endotheliopathy of COVID-19 and septic syndromes

Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: a single-center prospective longitudinal study

Endothelium activation markers in severe hospitalized COVID-19 patients: role in mortality risk prediction

Association of the angiopoietin/Tie2 and VEGF-A pathways with clinical and laboratory markers of disease severity in COVID-19

Morphological and functional alterations in endothelial colonyforming cells from recovered COVID-19 patients

Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses

Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2 infected endothelial cell model

A 3D in vitro model of inflammation-associated bleeding